New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 28, 2014
16:24 EDTSNN, VRX, DDD, SYK, AGN, DSW, TWTROn The Fly: Closing Wrap
Stocks on Wall Street finished lower following a session that began in quiet fashion and remained that way throughout the day. The volume was light, the trading range was tight, and the news flow failed to produce a catalyst that brought buyers into the fray. The S&P 500 touched an all-time high during the session, but was unable to hold onto its narrow gains into the close. Investors will have a busier economic calendar to look forward to tomorrow, which will include the first quarter annualized GDP numbers, weekly jobless claims data, a personal consumption reading, and energy inventory reports. ECONOMIC EVENTS: In the U.S., no major economic data was released. In Europe, a measure of business confidence In the euro area increased to 0.37 in May from 0.28 in April. COMPANY NEWS: Shares of Allergan (AGN) fell $8.90, or 5.39%, to $156.12 after Valeant Pharmaceuticals (VRX) raised the cash portion of its takeover bid by $10 to $58.30, along with 0.83 of a Valeant share and a new contingent value right, or CVR, related to DARPin sales which would provide up to approximately $25.00 per share of additional value. Wells Fargo calculated that, based on Valeant's closing price yesterday, the total new offer for Allergan is around $166 per share, which the firm believes may still be insufficient for Allergan. Following the new bid, which Allergan said it will "carefully review and consider," Valeant shares slid $3.00, or 2.31%, to $126.95. MAJOR MOVERS: Among the notable gainers was Twitter (TWTR), which climbed $3.26, or 10.69%, to $33.77 after Japanese bank Nomura upgraded the stock to Buy from Neutral in a note to investors. Also higher was Stryker (SYK), which rose $2.28, or 2.84%, to $82.64 after Financial Times reported this morning that the company was preparing a takeover bid for its U.K-based rival Smith & Nephew (SNN) and Stryker's CEO reportedly confirmed in an interview that the company was in the early stages of evaluating a potential acquisition of its peer. However, Stryker, at the urging of a British regulator, said it does not intend to make an offer for Smith & Nephew at this time, but reserved the right to make a future bid. Smith & Nephew shares trading in New York advanced $2.71, or 3.37% to $83.05. Among the noteworthy losers was shoe retailer DSW (DSW), which fell $8.90, or 27.37%, to $23.62 and was downgraded at Sterne Agee and Citigroup after its quarter report and yearly profit outlook disappointed. Also lower was 3D Systems (DDD), which slipped $6.20, or 10.95%, to $50.44 after announcing a secondary offering of about 6 million shares. INDEXES: The Dow fell 42.32, or 0.25%, to 16,633.18, the Nasdaq dropped 11.99, or 0.28%, to 4,225.08, and the S&P 500 declined 2.13, or 0.11%, to 1,909.78.
News For AGN;VRX;TWTR;SYK;SNN;DSW;DDD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 >>
November 16, 2015
06:33 EDTAGNPfizer, Allergan deal brings focus on U.S. tax-inversion deals, Reuters says
Pfizer's (PFE) takeover bid for Allergan (AGN) has refocused financial markets over a potential move by the U.S. Treasury Department against tax-inversion deals, Reuters reported Friday. The outlook for such a move remained unclear on Friday, the report says. Reference Link
November 15, 2015
18:13 EDTAGNAllergan, Pfizer targeting late November merger deal, FT says
Subscribe for More Information
November 13, 2015
16:08 EDTVRXRuane reports 10.52% passive stake in Valeant
Subscribe for More Information
14:41 EDTAGNAllergan presents EARLY analysis data at AAO meeting
Allergan announced that a post-hoc analysis of best corrected visual acuity data in diabetic macular edema patients treated with anti-vascular endothelial growth factor, or anti-VEGF, therapy suggests that long-term response in anti-VEGF treatment of DME can be assessed after three injections. Pravin Dugel, M.D., Clinical Professor, USC Eye Institute, Keck School of Medicine, University of Southern California and Managing Partner of Retinal Consultants of Arizona, said, "This data suggests that if treatment goals are not achieved after three injections, further expected improvement may be minimal and physicians may want to consider other treatment strategies."
11:12 EDTAGNPiper sees Pfizer profiting from Allergan deal, worth $50/share even without one
An acquisition of Allergan (AGN) by Pfizer (PFE) would increase the latter company's profits in 2016-2017 and lift its earnings by a large amount by 2019, wrote research firm Piper Jaffray in a note to investors today. WHAT'S NEW: By 2019, an acquisition of Allergan would increase Pfizer's earnings per share by 13%-16%, estimated Piper analyst Richard Purkiss. The deal would be profitable for Pfizer as early as 2016, the analyst believes. Excluding any acquisition, Pfizer is worth over $50 per share, well above analysts' average price target of $40, Purkiss believes. He kept a $52 price target and Overweight rating on Pfizer. WHAT'S NOTABLE: Yesterday dealReporter, noting that an acquisition of Allergan by Pfizer would be "a giant inversion deal," asserted that the U.S. Treasury could look to take steps to limit or discourage those types of transactions. On November 6, research firm Bernstein said that Allergan's strong results, coupled with the weakness of drug stocks, could cause Allergan to be reluctant to sell itself to Pfizer in the near-term. As a result, the firm thinks that the odds of a deal getting done may be lower than many believe. It kept a $385 price target and Outperform rating on Allergan. PRICE ACTION: In late morning trading, Pfizer rose fractionally to $33.47 and Allergan added 1.3% to $303.87.
10:49 EDTAGNMylan jumps, Perrigo plunges after hostile takeover bid fails
Shares of Mylan (MYL) jumped after the company's offer to acquire Perrigo (PRGO) failed. Perrigo shares fell after the news. WHAT'S NEW: Mylan's approximately $26B hostile takeover offer for Perrigo officially fell through Friday morning, ending a seven-month ordeal between the two companies. Mylan said that only about 40% of Perrigo's shares were tendered by the company's stockholders, falling short of the 50% required for an acquisition, forcing the offer to lapse after failing to meet its goal by the established deadline. In response to the news, Perrigo Chief Executive Officer Joseph Papa said he was "delighted" that his company's shareholders rejected the offer. "We have said all along that this offer from Mylan was a bad deal for our shareholders, as it significantly undervalued our durable business model and industry-leading future growth prospects," Papa said. Perrigo added that it will immediately commence its previously announced $2B share buyback and that it intends to complete $500M of the planned repurchase by the end of the year. WHAT'S NOTABLE: On July 27, Teva (TEVA) withdrew a takeover offer for Mylan amid Mylan's talks with Perrigo. The Israeli pharmaceutical company opted instead to purchase Allergan's (AGN) generics business. Commenting on its failure to buy Perrigo, Mylan Executive Chairman Robert Coury said in a statement that while the company viewed Perrigo as a "unique and exciting company," it was not required for the future success of the company. Coury said, "We are well-positioned to quickly execute on the next strategic, value-enhancing opportunities for our business, some of which we have already identified." STREET RESEARCH: Citi analyst Liav Abraham upgraded Mylan to Buy and raised her price target for shares to $59 from $52, saying that an overhang has been removed since the company's hostile attempt to buy Perrigo has fallen through. Abraham argued that a combination of the two companies would have been both destructive to both earnings and value for Mylan and that the failed bid will increase management's optionality to pursue other value-enhancing opportunities and enable investors to focus on the company's base business. In addition, RBC Capital Markets analyst Randall Stanicky confirmed a Sector Perform rating for both Mylan and Perrigo with price targets of $60 and $176, respectively. Stanicky said he expects Mylan's stock to gain 10%-15% towards $50 as a result of the news, while Perrigo will probably see a pull-back into the low $140s. The analyst added that the removal of the Mylan bid will drive initial weakness for Perrigo's shares but that the stock can settle close to its current levels. PRICE ACTION: In morning trading, Mylan rallied 12.5% to $48.60 and Perrigo fell 6.92% to $145.72. OTHERS TO WATCH: Teva shares trading in New York increased 0.26%, Allergan was up 0.66%, and Endo (ENDP), with which Reuters reported Perrigo held unsuccessful takeover talks, gained 5.56%.
10:00 EDTSYKOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Abbott (ABT) downgraded to Neutral from Buy at Goldman... Advance Auto Parts (AAP) downgraded after Q3 miss at Sterne Agee CRT... CafePress (PRSS) downgraded to Underperform from Market Perform at Raymond James... (CTRP) downgraded to Outperform from Strong Buy at Raymond James... CubeSmart (CUBE) downgraded to Outperform from Strong Buy at Raymond James... Deutsche Bank (DB) downgraded to Neutral from Buy at Citi... Digital Ally (DGLY) downgraded to Neutral from Buy at Roth Capital... El Pollo Loco (LOCO) downgraded to Neutral at Baird... F5 Networks (FFIV) downgraded to Market Perform from Outperform at William Blair... FirstMerit (FMER) downgraded on stock outperformance at Raymond James... Fly Leasing (FLY) downgraded to Underweight from Neutral at JPMorgan... GameStop (GME) downgraded on valuation, digital impact at Pacific Crest... Histogenics (HSGX) downgraded to Neutral from Buy at BTIG... MaxPoint (MXPT) downgraded to Hold from Buy at Needham... Memorial Resource (MRD) downgraded to Outperform at Scotia Howard Weil... Rite Aid (RAD) downgraded to Neutral from Overweight at JPMorgan... Rubicon Minerals (RBY) downgraded to Sell from Hold at Canaccord... SABMiller (SBMRY) downgraded to Hold from Buy at Berenberg... Sensata (ST) downgraded at SunTrust... Stryker (SYK) downgraded to Neutral from Buy at Goldman.
09:03 EDTDDD3D Systems announces two healthcare collaborations
Subscribe for More Information
08:22 EDTAGNAmerican Academy of Ophthalmology to hold annual meeting
AAO 2015 is being held in Las Vegas, Nevada on November 13-17 with webcasted presentations to begin on November 13 at 11:50 am. Webcast Link
06:54 EDTAGNPiper sees Pfizer worth over $50/share on standalone basis
Subscribe for More Information
06:27 EDTSYKStryker downgraded to Neutral from Buy at Goldman
Subscribe for More Information
06:24 EDTSYKMedtronic upgraded to Conviction Buy from Buy at Goldman
Goldman Sachs analyst David Roman upgraded Medtronic (MDT) to Conviction Buy saying the stock's risk/reward is compelling at current levels. The company's fundamentals are the strongest in nearly a decade amid improving end-markets, new product launches and financial flexibility, Roman tells investors in a research note. He raised his price target for shares to $90 from $87. Roman removed Stryker (SYK) from the Conviction List and also downgraded Abbott (ABT) to Neutral.
November 12, 2015
13:45 EDTAGNPfizer, Allergan talks could set off further Treasury action, dealReporter says
Subscribe for More Information
10:00 EDTSYKOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Accuray (ARAY) initiated with a Sell at Citi... Becton Dickinson (BDX) initiated with a Neutral at Citi... Boston Scientific (BSX) initiated with a Buy at Citi... Bruker (BRKR) initiated with a Buy at Stifel... C.R. Bard (BCR) initiated with a Buy at Citi... Cepheid (CPHD) initiated with a Buy at Stifel... CorMedix (CRMD) initiated with a Buy at Rodman & Renshaw... CoreSite Realty (COR) initiated with a Buy at BB&T... Digital Realty (DLR) initiated with a Buy at BB&T... DuPont Fabros (DFT) initiated with a Hold at BB&T... Duke Realty (DRE) initiated with a Hold at BB&T... Edwards Lifesciences (EW) initiated with a Sell at Citi... Electronic Arts (EA) initiated with an Outperform at Oppenheimer... EyeGate (EYEG) initiated with a Buy at Maxim... Glu Mobile (GLUU) initiated with a Perform at Oppenheimer... Integra LifeSciences (IART) initiated with a Buy at Citi... Intuitive Surgical (ISRG) initiated with a Buy at Citi... Mast Therapeutics (MSTX) initiated with a Buy at Maxim... Medgenics (MDGN) initiated with a Buy at Needham... Novocure (NVCR) initiated with a Buy at Evercore ISI... Prologis (PLD) initiated with a Hold at BB&T... QIAGEN (QGEN) initiated with a Hold at Stifel... Rocket Fuel (FUEL) initiated with a Neutral at Boenning & Scattergood... STAG Industrial (STAG) initiated with an Underweight at BB&T... Stryker (SYK) initiated with a Sell at Citi... Tremor Video (TRMR) initiated with an Outperform at Boenning & Scattergood... VOXX (VOXX) initiated with an Outperform at Oppenheimer... Varian Medical (VAR) initiated with a Neutral at Citi... Yahoo (YHOO) initiated with an Outperform at Boenning & Scattergood... YuMe (YUME) initiated with a Neutral at Boenning & Scattergood... Zimmer Biomet (ZBH) initiated with a Sell at Citi.
09:36 EDTTWTRActive equity options trading on open
Subscribe for More Information
08:12 EDTTWTRDorsey addresses dual role concerns in Square private meetings, NYT says
In intimate meetings with select potential investors in Square's (SQ) IPO, Jack Dorsey addressed concerns about his dual CEO role, explaining that he splits time equally between Square and Twitter (TWTR) a few days a week and then allocates his remaining time based on need, according to the New York Times, citing a person who attended one of them. Dorsey also emphasized the power of his team, the person told the Times. Reference Link
08:02 EDTVRXSynergy Pharmaceuticals still a saleable asset, says Canaccord
Canaccord still views Synergy Pharmaceuticals (SGYP) as a saleable asset, with Valeant (VRX) or Shire (SHPG) seen as the most obvious buyers. The firm also sees the cost of the launch of plecanatide as lower than expected and sees no need for the company to raise capital until at least the end of 2016. Canaccord reiterated its Buy rating and $19 price target on Synergy Pharmaceuticals shares.
06:23 EDTSYKZimmer Biomet initiated with a Sell at Citi
Subscribe for More Information
06:22 EDTSYKStryker initiated with a Sell at Citi
Citi analyst Amit Hazan started shares of Stryker (SYK) with a Sell rating and $88 price target. The analyst expects a slowdown in orthopedics and has a bearish view of the company's MAKO acquisition. Hazan sees downward revisions to consensus expectations. He also initiated Zimmer Biomet (ZBH) with a Sell rating.
06:12 EDTVRXAckman responds to Munger's Valeant criticism with Coke critique, Bloomberg says
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use